Crossmark

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)

Crossref DOI link: https://doi.org/10.1186/s40880-019-0414-4

Published Online: 2019-11-07

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Zhonghan http://orcid.org/0000-0003-1625-741X
Luo, Fan

Zhang, Yang

Ma, Yuxiang

Hong, Shaodong

Yang, Yunpeng

Fang, Wenfeng

Huang, Yan

Zhang, Li

Zhao, Hongyun
License Information

Text and Data Mining valid from 2019-11-07
More Information

Article History

Received: 3 August 2019

Accepted: 22 October 2019

First Online: 7 November 2019

Ethics approval and consent to participate

: This trial has been approved by the institutional review boards (ID: 2016-XY-023) and the independent ethics committees of Sun Yat-sen University Cancer Center (Ethic approval ID: 5010-2016-03). And other participating centers have also provided approval from their institutional review boards/independent ethics committees before enrollment. All patients were required to sign an informed consent form before enrollment.

: The authors are fully responsible for all content and editorial decisions were involved at all stages of manuscript development, and have approved the final version.

: Li Zhang has received research support from Hengrui Medicine Co. Ltd, Eli Lilly, Novartis Switzerland. Co. Ltd., Roche Shanghai. Co. Ltd., and Bristol-Myers Squibb Shanghai. Co. Ltd. All other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below